



Tatva Chintan Pharma Chem Limited

(CIN:L24232GJ1996PLC029894)



Date: 23 January 2024

Ref. No.: TCPCL/SEC/2023-24/00090

To,
The General Manager,
Corporate relationship department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001
Scrip Code: 543321

The Manager,
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex, Bandra(E),
Mumbai-400 051
Scrip Symbol: TATVA

Subject: Statement of Deviation / Variation in utilization of funds raised through QIP

Dear Sir/Madam,

Pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find enclosed herewith statement of deviation(s) or variation(s) in utilization of funds raised through Qualified Institutions Placement (QIP) for the quarter ended 31 December 2023 in the prescribed format. The same will be filed in XBRL mode separately.

We confirm that, as at 31 December 2023, there has not been any deviation(s) or variation(s) in the utilization of net proceeds of QIP as mentioned in the objects stated in the Placement Document dated 29 August 2023.

Report issued by Monitoring agency report will be separately filed with the exchange.

The above information shall be made available on the website of the Company at www.tatvachintan.com.

Kindly take the above information on your record.

Thanking You,

Yours Faithfully,
For Tatva Chintan Pharma Chem Limited

Ishwar Nayi
Company Secretary and Compliance Officer
M. No.: A37444

Encl.: As above



Tatva Chintan Pharma Chem Limited

(CIN:L24232GJ1996PLC029894)



Statement of Deviation/Variation in utilisation of funds raised:

Name of listed entity	Tatva Chintan Pharma Chem Limited
Mode of Fund Raising	Qualified Institutions Placement (QIP)
Description of mode of fund raising (Applicable in case of others is selected)	Not applicable
Date of Raising Funds	29-08-2023
Amount Raised (in Rs. million)	2000.00
Report filed for Quarter ended	31-12-2023
Monitoring Agency	Applicable
Monitoring Agency Name, if applicable	CRISIL Ratings Limited
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	No Comments
Comments of the auditors, if any	No Comments

Yours faithfully,

For Tatva Chintan Pharma Chem Limited

Chintan N. Shah

Chairman & Managing Director

DIN: 00183618

Place: Vadodara

Date: 23 January 2024

Registered Office and Factory : Plot No. 502/17, G.I.D.C. Estate, Ankleshwar - 393 002, District : Bharuch, Gujarat, India.

Dahej SEZ Unit : Plot No. Z/103/F/1 & 2, SEZ Area, Part-2, Dahej - 392 130, District : Bharuch, Gujarat, India.

Corporate Office and R & D Center (DSIR Approved) : Plot No. 353, G.I.D.C., Makarpura, Vadodara - 390 010, Gujarat, India.

Telephone No. : +91 75748 48533 / 34 **Fax :** +91 265 263 8533 **E-mail :** cs@tatvachintan.com **Website :** www.tatvachintan.com